Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Gain Therapeutics Inc (NASDAQ: GANX) was $2.55 for the day, down -14.14% from the previous closing price of $2.97. In other words, the price has decreased by -$14.14 from its previous closing price. On the day, 3.2 million shares were traded. GANX stock price reached its highest trading level at $3.13 during the session, while it also had its lowest trading level at $2.34.
Ratios:
Our analysis of GANX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $12.
On December 06, 2024, ROTH MKM started tracking the stock assigning a Buy rating and target price of $7.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 98078312 and an Enterprise Value of 83846640.
Stock Price History:
The Beta on a monthly basis for GANX is 0.07, which has changed by 0.21721315 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, GANX has reached a high of $4.34, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is -12.70%, while the 200-Day Moving Average is calculated to be 22.31%.
Shares Statistics:
GANX traded an average of 1.43M shares per day over the past three months and 2230760 shares per day over the past ten days. A total of 38.46M shares are outstanding, with a floating share count of 37.07M. Insiders hold about 3.62% of the company’s shares, while institutions hold 11.29% stake in the company. Shares short for GANX as of 1765756800 were 2073310 with a Short Ratio of 1.45, compared to 1763078400 on 1781339. Therefore, it implies a Short% of Shares Outstanding of 2073310 and a Short% of Float of 5.56.
Earnings Estimates
The performance of Gain Therapeutics Inc (GANX) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.63 and -$0.66 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.71, with 4.0 analysts recommending between -$0.55 and -$0.95.
